Evidence map›Paper›PMID 21829465›Full record

ArticlePloS one2011

Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma.

Derek J Nancarrow, Andrew D Clouston, B Mark Smithers, David C Gotley, Paul A Drew, David I Watson, Sonika Tyagi, Nicholas K Hayward, David C Whiteman, Australian Cancer Study and 1 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Genomics, Endoscopy, and Control of Gastroesophageal Cancers: A Perspective.Cellular and molecular gastroenterology and hepatology · 2017
    Review
  16. Clinical epigenetics · 2017
    Article
  17. Article
  18. Surrogate Markers: Lessons from the Next Gen?Cancer prevention research (Philadelphia, Pa.) · 2016
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Derek J NancarrowOncogenomics, Queensland Institute of Medical Research, Herston, Queensland, Australia. derekN@qimr.edu.au
Andrew D Clouston
B Mark Smithers
David C Gotley
Paul A Drew
David I Watson
Sonika Tyagi
Nicholas K Hayward
David C Whiteman
Australian Cancer Study
Study of Digestive Health
QIMR Berghofer Medical Research Institute · AUPrincess Alexandra Hospital · AUFlinders University · AUThe University of Adelaide · AUThe University of Queensland · AU

Funding

Molecular epidemiology of Barretts esophagus and cancerR01CA001833 · NCI · QUEENSLAND INSTITUTE OF MEDICAL RESEARCH · PI WHITEMAN, DAVID C · 2002 to 2006
$1.3M
NCI NIH HHS CA 001833-03NCI NIH HHS R01 CA001833
6 · The paper itself

Abstract

Esophageal adenocarcinoma (EAC) has become a major concern in Western countries due to rapid rises in incidence coupled with very poor survival rates. One of the key risk factors for the development of this cancer is the presence of Barrett's esophagus (BE), which is believed to form in response to repeated gastro-esophageal reflux. In this study we performed comparative, genome-wide expression profiling (using Illumina whole-genome Beadarrays) on total RNA extracted from esophageal biopsy tissues from individuals with EAC, BE (in the absence of EAC) and those with normal squamous epithelium. We combined these data with publically accessible raw data from three similar studies to investigate key gene and ontology differences between these three tissue states. The results support the deduction that BE is a tissue with enhanced glycoprotein synthesis machinery (DPP4, ATP2A3, AGR2) designed to provide strong mucosal defenses aimed at resisting gastro-esophageal reflux. EAC exhibits the enhanced extracellular matrix remodeling (collagens, IGFBP7, PLAU) effects expected in an aggressive form of cancer, as well as evidence of reduced expression of genes associated with mucosal (MUC6, CA2, TFF1) and xenobiotic (AKR1C2, AKR1B10) defenses. When our results are compared to previous whole-genome expression profiling studies keratin, mucin, annexin and trefoil factor gene groups are the most frequently represented differentially expressed gene families. Eleven genes identified here are also represented in at least 3 other profiling studies. We used these genes to discriminate between squamous epithelium, BE and EAC within the two largest cohorts using a support vector machine leave one out cross validation (LOOCV) analysis. While this method was satisfactory for discriminating squamous epithelium and BE, it demonstrates the need for more detailed investigations into profiling changes between BE and EAC.

Indexed as

Gene Expression ProfilingAdenocarcinomaAdolescentAdultAgedAged, 80 and overBarrett EsophagusBiomarkers, TumorCarcinoma, Squamous CellCase-Control StudiesCell ProliferationEsophageal NeoplasmsEsophagusFemaleGenome, HumanHumansBiomarkers, TumorRNA, Messenger

Identifiers

PMID21829465
PMCPMC3145652
OpenAlexW2081600712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.